MannKind Corporation (NASDAQ:MNKD) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2019, MannKind Corporation issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1. Press release dated November 6, 2019
MANNKIND CORP Exhibit
EX-99.1 2 mnkd-ex991_6.htm EX-99.1 mnkd-ex991_6.htm EXHIBIT 99.1 MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results Conference Call to Begin Today at 9:00 AM ET • 3Q 2019 Total Revenues of $14.6 million; +227% vs. 3Q 2018 o 3Q 2019 Afrezza Net Revenue was $6.4 million; +46% vs. 3Q 2018 ▪ Afrezza sold to our marketing partner in Brazil for launch was $0.7 million o 3Q 2019 Collaborations and Services Revenue was $8.2 million • Debt financing completed providing up to $75.0 million in non-dilutive capital • Received second $12.5 million milestone payment from United Therapeutics in November 2019 • Advanced Technosphere® formulations of sumatriptan and tadalafil into nonclinical pharmacology studies WESTLAKE VILLAGE,…
To view the full exhibit click here
About MannKind Corporation (NASDAQ:MNKD)
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
